Optipharm.CO.LTD Total Assets
Optipharm.CO.LTD total assets. Based on the latest financial reports, Optipharm.CO.LTD (153710) holds total assets worth ₩39.96 Billion KRW (≈ $27.08 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is Optipharm.CO.LTD worth for the company's overall valuation and market capitalisation.
Total Assets of Optipharm.CO.LTD (2015–2025)
Total assets of Optipharm.CO.LTD from 2015 to 2025. This chart illustrates how Optipharm.CO.LTD's total assets have evolved over time, based on quarterly financial data. See 153710 share price today for real-time trading data and today's change.
Optipharm.CO.LTD - Asset Composition Analysis
Optipharm.CO.LTD Total Assets Breakdown (December 2025)
Optipharm.CO.LTD total assets breakdown as of December 2025. Optipharm.CO.LTD's total assets of ₩39.96 Billion consist of 37.4% current assets and 62.6% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 5.6% |
| Accounts Receivable | ₩1.44 Billion | 3.5% |
| Inventory | ₩2.37 Billion | 5.8% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩270.42 Million | 0.7% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2015–2025)
This chart illustrates how Optipharm.CO.LTD's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore 153710 current assets to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Optipharm.CO.LTD's current assets represent 37.4% of total assets in 2025, an increase from 14.6% in 2015.
- Cash Position: Cash and equivalents constituted 5.6% of total assets in 2025, up from 3.5% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2015.
- Asset Diversification: The largest asset category is inventory at 5.8% of total assets.
Optipharm.CO.LTD Competitors by Total Assets
Key competitors of Optipharm.CO.LTD based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Revvity Inc.
NYSE:RVTY
|
USA | $12.00 Billion |
|
Diagnósticos da América S.A
SA:DASA3
|
Brazil | R$21.10 Billion |
|
SMO ClinPlus Co. Ltd.
SHE:301257
|
China | CN¥1.52 Billion |
|
Monash Ivf Group Ltd
AU:MVF
|
Australia | AU$512.35 Million |
|
RHYTHM Biosciences Ltd
AU:RHY
|
Australia | AU$3.10 Million |
|
Bcal Diagnostics Ltd
AU:BDX
|
Australia | AU$7.66 Million |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$16.78 Billion |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
Optipharm.CO.LTD - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.16 | 1.27 | 3.95 |
| Quick Ratio | 0.98 | 1.07 | 3.71 |
| Cash Ratio | 0.00 | 0.00 | 3.11 |
| Working Capital | ₩2.05 Billion | ₩3.69 Billion | ₩19.05 Billion |
Optipharm.CO.LTD - Advanced Valuation Insights
This section examines the relationship between Optipharm.CO.LTD's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.87 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -5.9% |
| Total Assets | ₩40.77 Billion |
| Market Capitalization | $45.68 Million USD |
Valuation Analysis
Below Book Valuation: The market values Optipharm.CO.LTD's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Optipharm.CO.LTD's assets decreased by 5.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Optipharm.CO.LTD (2015–2025)
The table below shows the annual total assets of Optipharm.CO.LTD from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩40.77 Billion ≈ $27.63 Million |
-5.89% |
| 2024-12-31 | ₩43.32 Billion ≈ $29.36 Million |
+10.30% |
| 2023-12-31 | ₩39.28 Billion ≈ $26.62 Million |
-4.63% |
| 2022-12-31 | ₩41.18 Billion ≈ $27.91 Million |
+0.03% |
| 2021-12-31 | ₩41.17 Billion ≈ $27.90 Million |
-0.37% |
| 2020-12-31 | ₩41.32 Billion ≈ $28.00 Million |
-0.96% |
| 2019-12-31 | ₩41.72 Billion ≈ $28.27 Million |
-2.16% |
| 2018-12-31 | ₩42.64 Billion ≈ $28.90 Million |
+114.87% |
| 2017-12-31 | ₩19.84 Billion ≈ $13.45 Million |
-3.55% |
| 2016-12-31 | ₩20.58 Billion ≈ $13.94 Million |
+18.17% |
| 2015-12-31 | ₩17.41 Billion ≈ $11.80 Million |
-- |
About Optipharm.CO.LTD
Optipharm.CO.,LTD operates as a biomedical solution provider in South Korea. It also engages in animal disease diagnosis, animal medicine, bacteriophage, Medipig, xenogenic organs, VLP vaccines, xenotransplantation, and other optipharm products, as well as veterinary drug for feed additives and laboratory animal Medipig business. The company was formerly known as Optiparm Solution Co., Ltd. and c… Read more